Safety and Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2018-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, randomized, multi-site, safety and efficacy study in subjects with rotator cuff injuries.

Patients will fall into two categories: treatment group (12 subjects) and non-treatment or control group (six subjects). The treatment group will undergo a small liposuction procedure and receive rotator cuff repair treatment with an ultrasound-guided injection of 5cc adipose-derived stem cells (ADSCs) into the point of injury. The control group will receive a 5cc cortisone injection into the point of injury

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Adult Adipose-Derived Stem Cell Injection Into Partial Thickness Rotator Cuff Tears

NCT04077190

Rotator Cuff Tears

COMPLETED NA

Stem Cell Treatment for Regeneration of the Rotator Cuff (Lipo-Cuff Study)

NCT06505135

Rotator Cuff Tears Rotator Cuff Injuries Rotator Cuff Tear Arthropathy

ENROLLING_BY_INVITATION PHASE1

Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears

NCT03752827

Rotator Cuff Tear Rotator Cuff Tendinitis

ACTIVE_NOT_RECRUITING NA

Clinical Study on the Safety and Efficacy of Tendon Stem Progenitor Cells Therapy for Rotator Cuff Tears

NCT07320378

Rotator Cuff Tendinopathy

NOT_YET_RECRUITING EARLY_PHASE1

Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease

NCT02474342

Rotator Cuff Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objectives of this study were to evaluate the safety of adult Adipose-Derived Stem Cell (ADRC) injection into partial thickness rotator cuff tears as indicated through adverse event rate and efficacy of pain and function through Rand short form-36 questionnaire and ASES Shoulder Score health questionnaires.

The secondary objective of this study was to assess the efficacy of adult ADRC injection into partial thickness rotator cuff tears through MRIs pre-and post-injection for the therapeutics intent to treat a rotator cuff injury.

Patients enrolled on this study received either ADRC (i.e., investigational treatment group) or TAU (i.e., control group). The investigational treatment group underwent a small liposuction procedure and received rotator cuff repair treatment with an ultrasound-guided injection of 5cc ADRCs into the point of injury. The control group received a 5cc cortisone injection. All patients, regardless of treatment, were followed up as indicated on the schedule of events table in the clinical study protocol.

Two clinical trial sites (Sioux Falls, SD and Fargo ND) enrolled subjects in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rotator Cuff Tear - Partial Thickness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

adipose-derived stem cell injection

ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)

Group Type EXPERIMENTAL

Adipose derived regenerative cells

Intervention Type BIOLOGICAL

cortisone injection

ultrasound guided injection of cortisone

Group Type ACTIVE_COMPARATOR

Cortisone Injectable

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adipose derived regenerative cells

Intervention Type BIOLOGICAL

Cortisone Injectable

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ADRCs steroid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females 30-75 years of age.
2. Clinical symptoms consistent with a rotator cuff lesion including but not limited to pain, muscle weakness, or active-limited range of motion (AROM).
3. Subjects who have not responded to physical therapy treatments for at least six weeks.
4. Subjects with \> 70% passive range of motion (PROM).
5. Diagnosed with \>50% tear to supraspinatus muscle or \< 5mm separation assessed by MRI.
6. Diagnosed with a partial-thickness rotator cuff tear
7. The ability of subjects to give appropriate consent or have an appropriate representative available.

Exclusion Criteria

1. Age \<30 or \> 75
2. Insufficient amount of subcutaneous tissue to allow recovery of 50cc of lipoaspirate.
3. History of systemic malignant neoplasms within last 5 years.
4. History of local neoplasm within the last 6 months and any history of local neoplasm at site of administration.
5. Subject is receiving immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.).
6. Subjects who are known to be HIV positive
7. Patients who have received a corticosteroid injection in rotator cuff site within last 3 months
8. Severe arthrosis of the glenohumeral or acromioclavicular joint
9. Irreparable rotator cuff tear (including rotator cuff tear arthropathy)
10. Fatty atrophy above Grade 2 in affected shoulder
11. Previous shoulder surgeries in affected shoulder
12. History of tobacco use within the last 3 months
13. Any contraindications to MRI scan according to MRI guidelines, or unwillingness to undergo MRI procedures
14. Patients on an active regimen of chemotherapy
15. Patients with a documented history of liver disease or an ALT value \>400
16. Allergy to sodium citrate of any "caine" type of local anesthetic
17. Patients pregnant or breast feeding
18. Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. This includes completion of Patient Reported Outcome instruments.
19. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
20. Subject is part of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include: Individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
21. Uncooperative patients or those with neurological/psychiatric disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No